Professor Thomas Baumert, Founder of Alentis Therapeutics Receives Mémain-Pelletier, French Academy of Science

RAYUS Radiology Quality Institute Distinguished Nationally by Centers for Medicare & Medicaid

Quality Institute Again Earns Certification as Provider-Led Entity for Advanced Diagnostic Imaging Guidance to Clinicians.

LX1550 Multiparameter Remote Monitoring Platform Receives FDA 510 (k) Approval: Reports LifeSignals

Further validation of ability to deliver continuous remote patient vital signs monitoring within both hospital and home settings.

U.S. News & World Report Names Tampa General Hospital as Best in Tampa Bay

This is the sixth consecutive year that Tampa General has been named by U.S. News & World Report as Tampa Bay's top hospital.

December 24, 2020

Professor Thomas Baumert, founder of Alentis Therapeutics has been awarded the Mémain-Pelletier, French Academy of Science award for his ground-breaking research into understanding the pathogenesis of liver cancer.

Professor Thomas Baumert said, “It’s a great honor and a mark of recognition for my team, my colleagues and collaborators, some 50 in all. Now we are going to have to redouble our efforts, with a view to bringing our research to patients so they can truly benefit.”

“Liver cancer is the second deadliest cancer, and the numbers are increasing sharply, due in particular to metabolic diseases, obesity and alcohol,” said Prof. Thomas Baumert. “It kills 800,000 people a year worldwide. Millions of people are at risk and treatments are not very effective, especially if detection is too late.”

The role fibrosis plays in the genesis of liver cancer is devastatingly clear. This is why Alentis is developing new medicines to treat, and even reverse the effects of liver fibrosis. To date, patients have few treatment options available to them. Prof. Thomas Baumert is recognized as a world-leading authority in the field of liver disease.

Alentis CEO Roberto Iacone said, “We’re tremendously proud of Thomas and the team. His academic excellence is second to none and this award speaks for itself. Alentis is embracing the enormous responsibility of bringing effective medicine to patients.”

Prof. Baumert is the founder of Alentis, a Professor of Medicine, and heads the Inserm Research Institute for Viral and Liver Diseases at the University of Strasbourg. Moreover, he is Director of the Laboratory of Excellence HEPSYS at the University of Strasbourg, and Hepatologist at the Center for Liver and Digestive Disease at the Strasbourg University Hospital. He was a fellow at Harvard Medical School, Massachusetts General Hospital, the Liver Diseases Branch at the National Institutes of Health, Bethesda Maryland, and the BROAD Institute of Harvard and MIT.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.